The interleukin (IL)-6/glycoprotein (GP)130/signal transducer and activator of transcription (STAT)3 pathway is emerging as a target for the treatment of hepatocellular carcinoma. IL-6 binds to IL-6R, forming a binary complex, which further combines with GP130 to transduce extracellular signaling by activating STAT3. Therefore, blocking the interaction between IL-6 and GP130 may inhibit the IL-6/GP130/STAT3 signaling pathway and its biological effects. It has been reported that bazedoxifene acetate (BAZ), a selective estrogen receptor modulator approved by the US Food and Drug Administration, could inhibit IL-6/GP130 protein-protein interactions. Western blot, immunofluorescence staining, wound healing and colony formation assays were used to detect the effect of BAZ on liver cancer cells. Cell viability was evaluated by MTT assay. Apoptosis of cells was determined using the Annexin V-FITC detection kit. Mouse xenograft tumor models were utilized to evaluate the effect of BAZ in vivo. Our data showed that BAZ inhibited STAT3 phosphorylation (P-STAT3) and expression of STAT3 downstream genes, inducing apoptosis in liver cancer cells. BAZ inhibited P-STAT3 induced by IL-6, but not by leukemia inhibitory factor. BAZ inhibited P-STAT1 and P-STAT6 less significantly as elicited by interferon-α, interferon-γ and IL-4. In addition, pretreatment of BAZ impeded the translocation of STAT3 to nuclei induced by IL-6. BAZ inhibited cell viability, wound healing and colony
| INTRODUC TI ON
Human hepatocellular carcinoma (HCC) is the second leading cause of cancer death in men worldwide in less developed countries, while it is the sixth cause of death in males of developed countries.
Worldwide, 782 500 new cases of HCC were diagnosed in 2012
and it was responsible for 745 500 deaths that year.
1 Numbers of new cancer cases and deaths estimated by the American Cancer
Society indicate that incidence rates of liver cancer in the USA have increased by approximately 3% per year in women and 4% in men. 2 In China, liver cancer is the third leading cause in selected cancer deaths and accounted for approximately 15% of all estimated deaths during 2015. 3 Due to a lack of incipient symptoms, HCC is often noticed and diagnosed at a late stage when potentially curative therapies, such as chemotherapy, chemoembolization, ablation and proton-beam therapy, are less effective. Moreover, resection of even very early tumors is linked to a recurrence rate of approximately 60% in 5 years, indicating a poor prognosis accompanied by a low 5-year survival rate in the majority of patients with HCC. 4 Aberrant modulation of cell proliferation and apoptosis is frequently associated with the development and progression of HCC. Despite plenty of studies that have contributed to the exploration of HCC, the exact pathophysiological process that accounts for the initiation and progression of HCC remains obscure, indicating that it may be promising and essential to study the molecular mechanisms involved with an aim to develop novel effective therapies.
The interleukin (IL)-6/glycoprotein (GP)130/signal transducer and activator of transcription (STAT)3 pathway has been emerging as a target for the treatment of HCC. [5] [6] [7] Previous studies have provided abundant supporting evidence that HCC involves the dysregulation of proteins, especially STAT3. 8 STAT3 can be phosphorylated and activated by the Janus kinase (JAK1-JAK3) family of tyrosine kinases, which plays a pivotal role in the development of both solid and hematopoietic malignancies. STAT3, an important member of the STAT family, is persistently activated in a wide variety of human malignancies. Indeed, activated STAT3 is necessary not only for oncogenesis and tumor progression, but also for invasion of HCC in vitro and in vivo. 9, 10 Levels of cytokines were found to be elevated in HCC, especially IL-6. 11,12 IL-6 binds to IL-6R to form a binary complex and further combines with GP130 to transduce extracellular signaling.
Therefore, blocking the interaction between IL-6 and GP130 may inhibit the IL-6/GP130/STAT3 signaling pathway and its biological effects. 13 The excessive expression of IL-6 contributes to the pathological progression in HCC through STAT3 activation, such as in hepatocarcinogenesis, 14, 15 and treatment of postmenopausal osteoporosis. [28] [29] [30] It has been reported that bazedoxifene acetate is a novel inhibitor of IL-6/GP130
protein-protein interaction, determined by the computational strategy for fragment-based drug design through combining multiple ligand simultaneous docking and repositioning. 31 However, there are still no reports of the effects of bazedoxifene on human liver cancer cells in vitro or in vivo.
| MATERIAL S AND ME THODS
This investigation has been conducted in accordance with the ethical standards according to national and international guidelines and has been approved by the institutional review board of Tongji Hospital. 
| Human liver cancer cell lines

| IL-6/GP130 inhibitor
Small molecular IL-6/GP130 inhibitor bazedoxifene was purchased from Cayman Chemical (Ann Arbor, MI, USA). Bazedoxifene was dissolved in sterile dimethyl sulfoxide (DMSO; Sigma) to make 20 mmol/L stock solution, stored at −20° until use.
| Cell viability
MTT cell viability assay kits were purchased from Promoter Biotechnology (Wuhan, China). SSMC 7721 and HUH-7 were seeded in 96-well plates (5000 cells/well). They were cultured with DMEM/ high glucose containing 10% FBS and 1% penicillin/streptomycin. 
| Colony formation
Cells were planted in six-well cell culture plates and were treated with or without bazedoxifene (20, 25 μmol/L) for 2 hours. Then, the treated cells were determined, stained with trypan blue (Promoter Biotechnology) and counted. Viable cells of low cell density (5000/ plate) were then seeded on 10-cm plates and grown for 3 weeks.
Cells were washed with phosphate-buffered saline (PBS) three times and fixed with cold methanol for 15 minutes. Then, cells were stained with 0.5% crystal violet in 25% methanol for 15 minutes.
| Western blot
Human liver cancer cells were treated with bazedoxifene ( 
| Immunofluorescence staining
Hep3B cells were seeded on glass cover slips on six-well plates and grown for 12 hours. The next day, the cells were cultured in serumfree medium for 12 hours, and pretreated with bazedoxifene for 
| Wound healing
HUH-7, 7721 and HEPG2 cell lines were seeded in six-well cell culture plates with DMEM/high glucose containing 10% FBS. When cells grew to a confluence of 100%, we scratched the monolayer along the marked line using pipette tips and plates were washed once to remove non-adherent cells. After washing, cells were treated with bazedoxifene (DMSO, 10, 15 μmol/L) for 2 hours. After that, the medium was removed and fresh medium supplemented with 10% FBS was added. Cells were allowed to migrate into the scratched area for an additional 24-36 hours without bazedoxifene, then images were captured.
| Annexin V-PI assay
Apoptosis was determined by fluorescence activated cell sorting (FACS) analysis using the Annexin V-FITC detection kit (KeyGEN BioTECH, Nanjing, China) as described by the manufacturer. HUH- CellQuest software was used to analyze apoptosis.
| Mouse xenograft tumor model
Human liver cancer cells, HEPG2 (10 7 cells in 100 μL of sterile PBS and matrigel), were injected s.c. into the right flank region of female athymic nude mice (4-6 weeks of age, 20-22 g). Three days after injection, the mice were randomized into control and treatment groups: (i) 5% DMSO and 10% Solutol added 85% hydroxypropyl B cyclodextrin (HPBCD) as vehicle control; and (ii) 5 mg/kg of bazedoxifene (dissolved in 5% DMSO, 10% Solutol and 85% HPBCD).
Bazedoxifene was administrated through intragastric gavage once a day for 20 days. Tumor growth was determined by measuring the length (L) and width (W) of the tumor every other day with a caliper. Tumor volume was calculated using the following formula: vol- 
| Statistical analysis
Data were presented as the mean ± SD for at least three independent experiments. Statistical analyses were performed with SPSS software (version 13.0). The significant differences between any two groups were evaluated by one-way ANOVA. The value of P < 0.05 was considered statistically significant.
| RE SULTS
| Structure of bazedoxifene and the selective inhibitory effect on STAT3 phosphorylation induced by IL-6
Bazedoxifene is known as a selective estrogen receptor modulator ( Figure 1A ). In a previous study, we reported bazedoxifene as a novel inhibitor of IL-6/GP130 protein-protein interactions using multiple ligand simultaneously docking and drug repositioning approaches.
The Hep3B liver cancer cell line, which is considered estrogen receptor negative, 32 was used to examine whether bazedoxifene is ca- The expression of Survivin was decreased after treatment with bazedoxifene in HEPG2, 7721 and HUH-7 liver cancer cells as examined by western blot assay ( Figure 3 ). As to the expression of Bcl-2, it was decreased with the treatment of bazedoxifene in HEPG2 and HUH7 cell lines, but not significantly in 7721 cells ( Figure 3B ). Furthermore, we explored whether bazedoxifene had the potential to induce apoptosis in liver cancer cells. Our results showed that bazedoxifene promoted the cleavage of caspase-3, which is one of the hallmarks of apoptosis in these liver cancer cells (Figure 3 ).
| Bazedoxifene inhibits cell viability, wound healing and colony formation in liver cancer cells
The results suggested that bazedoxifene effectively inhibited activation of STAT3, suppressed the expression of its downstream target genes and induced apoptosis in human liver cancer cells in which STAT3 has been documented to be persistently activated. Therefore, we further examined whether bazedoxifene could affect STAT3-dependent cell migration, which may lead to invasion and metastasis.
MTT assays were used to examine whether bazedoxifene could suppress cell viability. In HEPG2, 7721 and HUH-7 liver cancer cells, treatment with bazedoxifene for 24 hours resulted in a dramatic decrease 
| Bazedoxifene suppresses the nuclear translocation of STAT3 induced by IL-6 without inhibition on nuclear translocation of STAT3 induced by LIF in Hep3B liver cancer cells
As previously reported, the majority of STAT3 were latent and localized in cytoplasm. The phosphorylation-dependent translocation of STAT3 from the cytoplasm to nuclei has been proven to be of importance for STAT3 to exhibit its biological effects as a transcription factor. To detect the inhibitory effect of bazedoxifene on STAT3 translocation, Hep3B cells were cultured in serum-free medium overnight on six-well plates.
Cells were pretreated with 20 μmol/L of bazedoxifene or DMSO for 2 hours followed by 25 ng/mL of IL-6 or LIF for another 30 minutes. In
Hep3B cells treated with IL-6, STAT3 was phosphorylated and translocated into the nucleus. However, most STAT3 was retained in the cytoplasm when pretreated with bazedoxifene (20 μmol/L) ( Figure 5A ).
We further found that the phosphorylation of STAT3 was inhibited with treatment of bazedoxifene by immunofluorescence staining (see Figure S1 ). Therefore, these results suggest that the inhibition of STAT3 
| D ISCUSS I ON
Many genetic alterations and critical molecular signaling pathways have been identified as having important roles contributing to the development and progression of HCC. STAT3 is frequently activated in many types of solid and blood cancers, including liver cancer and contributes to cancer progression. 17 In STAT3 knockout mice models, it has been shown that STAT3 was required for tumorigenesis in intestinal, skin and liver tissue. [33] [34] [35] In previous studies, constitutively activated STAT3 had been reported in a large proportion of cancers, where it contributed to cell growth, apoptotic resistance, angiogenesis and metastatic potential. 5, 35 Impediment of constitutive activation of STAT3 not only induced apoptosis in cancer cells, but also overcame chemoresistance and radioresistance. 36 Selectively targeting activated STAT3 signaling has been shown to be effective in inhibiting cancer-associated processes and cancer cell viability. 
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